Australian Clinical Labs (ASX:ACL) ROCE % : 15.91% (As of Jun. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Australian Clinical Labs ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Australian Clinical Labs's annualized ROCE % for the quarter that ended in Jun. 2024 was 15.91%.

Australian Clinical Labs ROCE % Historical Data

The historical data trend for Australian Clinical Labs's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Australian Clinical Labs ROCE % Chart

Australian Clinical Labs Annual Data

Trend

Dec20

Jun21

Jun22

Jun23

Jun24

ROCE %

34.90

72.04

13.06

10.62

Australian Clinical Labs Semi-Annual Data
	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
ROCE %	Get a 7-Day Free Trial			34.33	16.82	9.03	5.22	15.91

Australian Clinical Labs ROCE % Calculation

Australian Clinical Labs's annualized ROCE % for the fiscal year that ended in Jun. 2024 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Jun. 2024 )		(A: Jun. 2023 )		(A: Jun. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Jun. 2024 )		(A: Jun. 2023 )		(A: Jun. 2024 )
	=	41.223	/	( ( (578.913 - 187.925)	+	(593.06 - 207.703) )	/ 2 )
	=	41.223	/	( (390.988	+	385.357)	/ 2 )
	=	41.223	/	388.1725
	=	10.62 %

Australian Clinical Labs's ROCE % of for the quarter that ended in Jun. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Jun. 2024 )		(Q: Dec. 2023 )		(Q: Jun. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Jun. 2024 )		(Q: Dec. 2023 )		(Q: Jun. 2024 )
	=	61.976	/	( ( (583.723 - 189.992)	+	(593.06 - 207.703) )	/ 2 )
	=	61.976	/	( ( 393.731	+	385.357 )	/ 2 )
	=	61.976	/	389.544
	=	15.91 %

(1) Note: The EBIT data used here is two times the semi-annual (Jun. 2024) EBIT data.

Australian Clinical Labs (ASX:ACL) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Australian Clinical Labs ROCE % Related Terms

Thank you for viewing the detailed overview of Australian Clinical Labs's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Australian Clinical Labs Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Australian Clinical Labs Ltd (ASX:ACL) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

1868-1892 Dandenong Road, Clayton, VIC, AUS, 3168

Website

https://www.clinicallabs.com.au

Australian Clinical Labs, or ACL, is Australia's third-largest private pathology provider. ACL earns almost its entire group revenue from pathology services in Australia, which are mostly earned via the publicly funded health Medicare system. ACL is well-established in the states of Western Australia, South Australia, Victoria and the Northern Territory.

Australian Clinical Labs Headlines

No Headlines